Executive Vice President International Commercial Operations, Cepheid
Philippe Jacon joined Cepheid as Executive Vice President International Commercial Operations in January 2013. In this role he leads the International growth strategy of the company, encompassing both our commercial sales and our HBDC program.
Priro to Cepheid, Philippe Jacon held the position of CEO of the Foundation for Innovative New Diagnostics (FIND) since October 2011. As such, he lead the strategy of this not-for-profit, Geneva-based International Organization to ensure it fulfills its mission to “Drive the development and early implementation of innovative diagnostic tests that have a high impact on patient care and disease control in low-resource settings”.
Philippe Jacon joined FIND from EDMA (European Diagnostic Manufacturers Association) where he acted as the Director General ad interim since March of 2011.
Prior to EDMA, he spent most of his career with BD (Becton Dickinson and Co) in various positions and locations.
Most notably, he was Worldwide President of BD Diagnostics-Diagnostic Systems and Worldwide President of BD Diagnostics – Microbiology Systems both positions based in Baltimore, MD; VP/GM Europe BD Medical – Diabetes Care. Prior to these roles, Mr. Jacon held positions of increasing responsibility in BD Medical-Pharmaceutical Systems in Europe and subsequently in the US where he was the VP/GM for the business. Mr. Jacon started his career at BD as a Sales Representative in France for BD Biosciences.
During his time in Baltimore, Mr. Jacon played an active role in the community. He served on the board of the University of Maryland BioPark and the Greater Baltimore Committee. He was also appointed by Governor Martin O’Malley to the Maryland Life Sciences Advisory Board.
Philippe Jacon has a Microbiologist Engineer degree from the Université de Bretagne Occidentale in France. He is a French citizen, married and has 3 children.
1 blog from the author
Curbing the burden of disease through rapid diagnostics tools
Infectious diseases remain a source of concern in the EU due to the emergence of new resistance to anti-infective drugs. The EU is supporting the deployment of innovative solutions in low resource settings in the world with the aim to help the local populations avoid the emergence of new resistance that can spread across borders.